

## Microbicide Trials Network

### Clarification Memo #01 to:

#### MTN-002

### Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel among Healthy Term Gravidas Version 1.0 / 29 August 2007

#### DAIDS PROTOCOL #10600

#### IND # 55,690

**Date of Clarification Memorandum: 15 September 2008**

---

#### *Section 1: Summary of Clarifications and Rationale*

The procedures clarified in this Clarification Memorandum (CM) have been approved by the NIAID and NICHD Medical Officers and are to be implemented immediately upon issuance. IRB approval of this CM is not required by the sponsor; however, investigators may submit the CM to the IRB overseeing the study at their site for information.

This CM is official MTN-002 documentation. It is effective immediately. A copy of this CM must be retained in the study site's Essential Documents file for MTN-002.

No change in informed consent is necessitated or included in this CM.

The primary goal of this CM is to clarify the types of planned flow cytometry assays. Flow cytometry will be performed to evaluate for CD38 and HLA-DR expression (surrogates for cell activation and proliferation markers, respectively) as opposed to CD38 and CD95.

Further detail can be found in the section below.

---

#### *Section 2: Implementation*

Text to be deleted is noted by ~~strikethrough~~ and text to be added is noted below in **bold**.

1. In the third paragraph of Section 7.3, Pharmacokinetic Measures, flow cytometry for CD95 expression is replaced with flow cytometry for HLA-DR expression.

### 7.3 Pharmacokinetic Measures

For the purposes of scheduling subsequent evaluation and follow-up, the date of gel administration will be considered Day 0. The time of gel administration will be considered Time 0. Timed pharmacokinetic measures are timed by hours passed since gel administration, not cesarean section.

A physician investigator will not be the primary or first assistant surgeon for the cesarean section. A physician investigator will be responsible for collection of study-related specimens in the operating room.

Flow cytometry for CD38 and ~~CD95~~**HLA-DR** will be obtained pre-dose on Day 0. This will be required as a surrogate for cell activation and proliferation markers, respectively, to serve as covariates in the intracellular model building.